摘要
目的探讨在肾透明细胞癌患者血清中miRNA-106a表达水平及其与临床病理特征的关系,为后期深入研究提供参考数据。方法选取5例肾透明细胞癌肿瘤组织及瘤旁正常肾组织,对其进行miRNA芯片筛测,选出肾癌组织中异常表达的miRNA;收集28例肾癌患者术前血清样本(肾癌组),收集26例健康体检者血清样本作为对照组,采用实时荧光定量PCR技术检测肾癌患者和正常人血清中miRNA-106a的表达水平,分析肾癌患者术前血清miRNA-106a表达与临床病理特征的关系。结果 miRNA芯片检测肾细胞癌肿瘤组织中miRNA-106a较肿瘤旁肾脏正常组织明显增加,与对照组比较,肾癌组患者血清miRNA-106a显著上调,差异有统计学意义;不同性别、年龄、肿瘤直径、Fruhman分期患者血清miRNA-106a表达量差异均无统计学意义。结论 miRNA-106a在肾癌患者血清中高表达,可能对肾细胞癌的诊断具有一定临床价值。
Objective To detect plasma miRNA-106a expression in patients with renal cell carcinoma and analyze its correlation to the clinicopathological feature and disease diagnosis. Methods To screen out ab- normal expression miRNA in5 renal clear cell carcinoma tumor tissue and adjacent normal tissues using miRNA screening chip. 28 serum samples in patients with RCC was collected before surgery, 26 healthy controls were included, the expression level of miRNA-106a were detected by real-time PCR. Results Compared with the health control, the expression level of miRNA-106a in tissues with RCC is increased obviously. The serum miRNA-106a expression were up-regulated inin RCC samples. There were no statis- tical significance in miRNA-106a expression difference with gender, age, dismeter of tumor and Fruhrnan classification. Conclusion The expression level of miRNA-106a is closely related to RCC, miRNA-106a can be regarded as a potential molecular biomarker in RCC.
出处
《新疆医科大学学报》
CAS
2015年第9期1151-1154,共4页
Journal of Xinjiang Medical University
基金
新疆维吾尔自治区自然科学基金(2010211B22)
